Key clinical point: Evolocumab is safe, effective, and well-tolerated for LDL cholesterol owering in dyslipidemic HIV-positive patients.

Major finding: Dyslipidemic HIV-infected patients on background maximally tolerated lipid-lowering therapy experienced a 56.2% reduction in LDL after 24 weeks on evolocumab, compared to a 0.7% increase with placebo. Study details: This was a phase 3, randomized, double-blind, placebo-controlled study of 464 dyslipidemic HIV-infected patients.

Disclosures: The presenter reported receiving a research grant from Amgen, the study sponsor, as well as lecture fees from half a dozen other pharmaceutical companies.